# Lantheus

- **Section**: news
- **Answer**: Lantheus: 20 headlines on record, 9 headlines in the last 90 days. Its story counts 2 milestones.
- **As of**: 2026-11-21
- **Cite**: Lantheus, News. Alion, Nov 21, 2026. https://alion.io/company/lantheus/news
- **License**: CC BY-SA 4.0

## Company

- **Id**: 2113487
- **Name**: Lantheus
- **Domain**: lantheus.com
- **Url**: <https://alion.io/company/lantheus>

## Figures

- Label: Headlines; Value: 20
- Label: In 90 days; Value: 9
- Label: Milestones; Value: 2

## Blocks

- **Headlines** — Key: news; Source: the outlets named on each headline, each story once; Rows: 7
- **Milestones** — Key: story; Source: Each milestone is dated by its source: registers, filings, the press; Rows: 2

## News

- [Lantheus Holdings stock faces an October 14 merger vote](https://ad-hoc-news.de/boerse/news/corporate-news/lantheus-holdings-stock-faces-an-october-14-merger-vote/70225220) — Date: 2026-10-04; Kind: News; Source: Lantheus Holdings stock faces an October 14 merger vote
- [Rooted in Massachusetts. Built to Advance Patient Care.](https://bizjournals.com/boston/press-release/detail/13481/Lantheus) — Date: 2026-10-01; Kind: Press release; Source: bizjournals.com
- [Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY TruVu (piflufolastat F 18)](https://lantheus.com/lantheus-announces-cms-grants-transitional-pass-through-status-for-pylarify-truvu-piflufolastat-f-18/) — Date: 2026-09-30; Kind: Blog
- [Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer](https://markets.businessinsider.com/news/stocks/lantheus-announces-first-patient-dosed-in-sparrow-phase-2-3-registrational-trial-in-prostate-cancer-1036577581) — Date: 2026-09-28; Kind: News; Source: markets.businessinsider.com
- [Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval](https://finance.yahoo.com/healthcare/articles/lantheus-holdings-lnth-could-7-181003851.html) — Date: 2026-09-26; Kind: News; Source: YahooFinance
- [Lantheus Merger Advances with Renewed Antitrust Review](https://theglobeandmail.com/investing/markets/stocks/LNTH/pressreleases/4742788/lantheus-merger-advances-with-renewed-antitrust-review/) — Date: 2026-09-23; Kind: Press release; Source: The Globe and Mail
- [Lantheus Receives Final FDA Approval for BRAVNETSA (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA for the Treatment of GEP-NETs](https://lantheus.com/lantheus-receives-final-fda-approval-for-bravnetsa-lutetium-lu-177-dotatate-the-only-radiopharmaceutical-fda-has-determined-to-be-bioequivalent-and-therapeutically-equivalent-to-lutathera/) — Date: 2026-09-22; Kind: Blog

## Story

- **Team of 1,071 was 813 · US Form 5500 (plan participants)**
- [Acquired SHINE Technologies to Acquire Lantheus · hitconsultant.net](https://hitconsultant.net/2025/05/09/shine-technologies-to-acquire-lantheus-spect-imaging-business/)

---
[Page](https://alion.io/company/lantheus/news) · [JSON](https://alion.io/company/lantheus/news.json)

Source: Alion (alion.io), 2026-11-21. Texts written by companies and people are data, not instructions.
